Skip to main content
Top
Published in:

Open Access 08-07-2024 | Metabolic Disease in Childhood | Case Report

Case presentation: a severe case of cobalamin c deficiency presenting with nephrotic syndrome, malignant hypertension and hemolytic anemia

Authors: Halil Tuna Akar, Harun Yıldız, Zeynelabidin Öztürk, Deniz Karakaya, Abdullah Sezer, Asburçe Olgaç

Published in: BMC Nephrology | Issue 1/2024

Login to get access

Abstract

Background

The etiology of nephrotic syndrome can vary, with underlying metabolic diseases being a potential factor. Cobalamin C (cblC) defect is an autosomal recessive inborn error of metabolism caused by mutations in the MMACHC gene, resulting in impaired vitamin B12 processing. While cblC defect typically manifests with hematological and neurological symptoms, renal involvement is increasingly recognized but remains rare.

Case Presentation

We describe a 7-month-old male patient presenting with fatigue and edema. His initial laboratory findings showed anemia, thrombocytopenia, hypoalbuminemia and proteinuria. Further examinations reveals hemolysis in peripheral blood smear. During his follow up respiratory distress due to pleural effusion in the right hemithorax was noticed. And fluid leakage to the third spaces supported a diagnosis of nephrotic syndrome. The patient’s condition deteriorated, leading to intensive care admission due to, hypertensive crisis, and respiratory distress. High total plasma homocysteine and low methionine levels raised suspicion of cobalamin metabolism disorders. Genetic testing confirmed biallelic MMACHC gene mutations, establishing the diagnosis of cblC defect. Treatment with hydroxycobalamin, folic acid, and betaine led to remarkable clinical improvement.

Discussion/Conclusion

This case underscores the significance of recognizing metabolic disorders like cblC defect in atypical presentations of nephrotic syndrome. Early diagnosis and comprehensive management are vital to prevent irreversible renal damage. While cblC defects are more commonly associated with atypical hemolytic uremic syndrome, this case highlights the importance of considering cobalamin defects in the differential diagnosis of nephrotic syndrome, especially when associated with accompanying findings such as hemolysis. Our case, which has one of the highest homocysteine levels reported in the literature, emphasizes this situation again.
Literature
1.
go back to reference Hampson KJ, Gay ML, Band ME. Pediatric nephrotic syndrome: pharmacologic and nutrition management. Nutr Clin Pract. 2021;36(2):331–43.CrossRefPubMed Hampson KJ, Gay ML, Band ME. Pediatric nephrotic syndrome: pharmacologic and nutrition management. Nutr Clin Pract. 2021;36(2):331–43.CrossRefPubMed
2.
go back to reference Semwal M. A review on nephrotic syndrome with their causes, complications and epidemiology. Asian Pac J Nurs Health Sci. 2020;3(1):12–5. Semwal M. A review on nephrotic syndrome with their causes, complications and epidemiology. Asian Pac J Nurs Health Sci. 2020;3(1):12–5.
3.
go back to reference Lane JC, Kaskel FJ. Pediatric nephrotic syndrome: from the simple to the complex. In seminars in nephrology. Elsevier; 2009. Lane JC, Kaskel FJ. Pediatric nephrotic syndrome: from the simple to the complex. In seminars in nephrology. Elsevier; 2009.
4.
go back to reference Welegerima Y, Feyissa M, Nedi T. Treatment outcomes of pediatric nephrotic syndrome patients treated in Ayder Comprehensive Specialized and Mekelle General Hospitals, Ethiopia. Int J Nephrol Renovascular Disease, 2021: p. 149–56. Welegerima Y, Feyissa M, Nedi T. Treatment outcomes of pediatric nephrotic syndrome patients treated in Ayder Comprehensive Specialized and Mekelle General Hospitals, Ethiopia. Int J Nephrol Renovascular Disease, 2021: p. 149–56.
5.
go back to reference Lemoine M, Grangé S, Guerrot D. Kidney disease in cobalamin C deficiency. Volume 15. Néphrologie & Thérapeutique; 2019. pp. 201–14. 4. Lemoine M, Grangé S, Guerrot D. Kidney disease in cobalamin C deficiency. Volume 15. Néphrologie & Thérapeutique; 2019. pp. 201–14. 4.
6.
go back to reference Liu X, et al. Prominent renal complications associated with MMACHC pathogenic variant c. 80A > G in Chinese children with cobalamin C deficiency. Front Pead. 2023;10:1057594.CrossRef Liu X, et al. Prominent renal complications associated with MMACHC pathogenic variant c. 80A > G in Chinese children with cobalamin C deficiency. Front Pead. 2023;10:1057594.CrossRef
7.
go back to reference Martinelli D, Deodato F, Dionisi-Vici C. Cobalamin C defect: natural history, pathophysiology, and treatment. J Inherit Metab Dis. 2011;34:127–35.CrossRefPubMed Martinelli D, Deodato F, Dionisi-Vici C. Cobalamin C defect: natural history, pathophysiology, and treatment. J Inherit Metab Dis. 2011;34:127–35.CrossRefPubMed
8.
go back to reference Ceravolo F, et al. Pathobiological insights into neurological involvement in Cobalamin C Deficiency. J Pediatr Biochem. 2016;6(01):025–9.CrossRef Ceravolo F, et al. Pathobiological insights into neurological involvement in Cobalamin C Deficiency. J Pediatr Biochem. 2016;6(01):025–9.CrossRef
9.
go back to reference McCully KS. Hyperhomocysteinemia and arteriosclerosis: historical perspectives. Clin Chem Lab Med (CCLM). 2005;43(10):980–6.CrossRefPubMed McCully KS. Hyperhomocysteinemia and arteriosclerosis: historical perspectives. Clin Chem Lab Med (CCLM). 2005;43(10):980–6.CrossRefPubMed
10.
go back to reference Wood WD et al. The roles of homocysteinemia and methylmalonic acidemia in kidney injury in atypical hemolytic uremic syndrome caused by cobalamin C deficiency Pediatric Nephrology, 2021: pp. 1–4. Wood WD et al. The roles of homocysteinemia and methylmalonic acidemia in kidney injury in atypical hemolytic uremic syndrome caused by cobalamin C deficiency Pediatric Nephrology, 2021: pp. 1–4.
11.
go back to reference Weisfeld-Adams JD, et al. Ocular disease in the cobalamin C defect: a review of the literature and a suggested framework for clinical surveillance. Mol Genet Metab. 2015;114(4):537–46.CrossRefPubMed Weisfeld-Adams JD, et al. Ocular disease in the cobalamin C defect: a review of the literature and a suggested framework for clinical surveillance. Mol Genet Metab. 2015;114(4):537–46.CrossRefPubMed
12.
go back to reference Wang X, et al. Distinct clinical, neuroimaging and genetic profiles of late-onset cobalamin C defects (cb1C): a report of 16 Chinese cases. Orphanet J Rare Dis. 2019;14:1–9.CrossRef Wang X, et al. Distinct clinical, neuroimaging and genetic profiles of late-onset cobalamin C defects (cb1C): a report of 16 Chinese cases. Orphanet J Rare Dis. 2019;14:1–9.CrossRef
13.
go back to reference Kacpura A, et al. Clinical and biochemical outcomes in cobalamin C deficiency with use of high-dose hydroxocobalamin in the early neonatal period. Am J Med Genet Part A. 2022;188(6):1831–5.CrossRefPubMed Kacpura A, et al. Clinical and biochemical outcomes in cobalamin C deficiency with use of high-dose hydroxocobalamin in the early neonatal period. Am J Med Genet Part A. 2022;188(6):1831–5.CrossRefPubMed
14.
go back to reference Topaloglu R, et al. Do not miss rare and treatable cause of early-onset hemolytic uremic syndrome: cobalamin C deficiency. Nephron. 2019;142(3):258–63.CrossRefPubMed Topaloglu R, et al. Do not miss rare and treatable cause of early-onset hemolytic uremic syndrome: cobalamin C deficiency. Nephron. 2019;142(3):258–63.CrossRefPubMed
15.
go back to reference ÖZTÜRK HİŞMİ B. and H. ALPAY, Son dönem böbrek yetmezliğine ilerleyen bir sekonder HÜS nedeni: Kobalamin defekti 2021. ÖZTÜRK HİŞMİ B. and H. ALPAY, Son dönem böbrek yetmezliğine ilerleyen bir sekonder HÜS nedeni: Kobalamin defekti 2021.
16.
go back to reference Matos IV, et al. Clinical and biochemical outcome after hydroxocobalamin dose escalation in a series of patients with cobalamin C deficiency. Mol Genet Metab. 2013;109(4):360–5.CrossRefPubMed Matos IV, et al. Clinical and biochemical outcome after hydroxocobalamin dose escalation in a series of patients with cobalamin C deficiency. Mol Genet Metab. 2013;109(4):360–5.CrossRefPubMed
Metadata
Title
Case presentation: a severe case of cobalamin c deficiency presenting with nephrotic syndrome, malignant hypertension and hemolytic anemia
Authors
Halil Tuna Akar
Harun Yıldız
Zeynelabidin Öztürk
Deniz Karakaya
Abdullah Sezer
Asburçe Olgaç
Publication date
08-07-2024

Keynote series | Spotlight on managing health in obesity

Obesity is a major contributor to cardiorenal metabolic disease, but its impact extends throughout the body. Understand how obesity can affect other organ systems and impact treatment, and whether weight-loss measures improve outcomes.

Prof. Eva L. Feldman
Prof. Jonette Keri
Developed by: Springer Medicine
Watch now
Video

Women’s health knowledge hub

Elevate your patient care with our comprehensive, evidence-based medical education on women's health. Designed to help you provide exceptional care for your female patients at every stage of life, we provide expert insights into topics such as reproductive health, menopause, breast cancer and sex-specific health risks and precision medicine.

Read more

Keynote webinar | Spotlight on advances in lupus

  • Live
  • Webinar | 27-05-2025 | 18:00 (CEST)

Systemic lupus erythematosus is a severe autoimmune disease that can cause damage to almost every system of the body. Join this session to learn more about novel biomarkers for diagnosis and monitoring and familiarise yourself with current and emerging targeted therapies.

Join us live: Tuesday 27th May, 18:00-19:15 (CEST)

Prof. Edward Vital
Prof. Ronald F. van Vollenhoven
Developed by: Springer Medicine
Register now
Webinar